Integer Holdings Corporation (ITGR) Stock Analysis
Range Bound setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $90.66, but acceptable to hold if already in. Reasons: Concentration risk — Customer: Abbott Laboratories, Boston Scientific and Medtronic (49.0%); Analyst target reached - limited upside remaining.
Integer Holdings is a medical device CDMO manufacturing components and finished devices for Cardio & Vascular, Cardiac Rhythm Management, and Neuromodulation OEM customers from facilities in the U.S., Mexico, Ireland, and other countries. Top 3 customers (Abbott Laboratories,... Read more
Hold if already holding. Not a fresh buy at $90.66, but acceptable to hold if already in. Reasons: Concentration risk — Customer: Abbott Laboratories, Boston Scientific and Medtronic (49.0%); Analyst target reached - limited upside remaining. Chart setup: RSI 52 mid-range, Bollinger mid-band. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 4.4/10, moderate confidence.
Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity 45d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — Integer Holdings Corporation
Latest news
- NEWS Here's why you should retain Integer Holdings stock in your portfolio - MSN — MSN positive
- NEWS What To Expect From Integer Holdings’s (ITGR) Q1 Earnings - Yahoo Finance — Yahoo Finance neutral
- NEWS What To Expect From Integer Holdings’s (ITGR) Q1 Earnings - StockStory — StockStory neutral
- NEWS What To Expect From Integer Holdings’s (ITGR) Q1 Earnings - MSN — MSN neutral
- NEWS What To Expect From Integer Holdings’s (ITGR) Q1 Earnings - FinancialContent — FinancialContent neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerAbbott Laboratories, Boston Scientific and Medtronic49%10-K Item 1: 'During 2025, three of our customers, Abbott Laboratories, Boston Scientific and Medtronic were each in excess of 10% of total sales and collectively accounted for 49% of our total sales.'
Material Events(8-K, last 90d)
- 2026-03-12Item 5.02LOWPer Cooperation Agreement with Irenic Capital dated March 9, 2026, James F. Flanagan and Irenic-designated Aaron Kapito appointed to Board. Two incumbent directors will not stand for re-election at 2026 Annual Meeting.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $90.66, but acceptable to hold if already in. Reasons: Concentration risk — Customer: Abbott Laboratories, Boston Scientific and Medtronic (49.0%); Analyst target reached - limited upside remaining. Chart setup: RSI 52 mid-range, Bollinger mid-band. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $92.86 (+2.4%), stop $85.95 (−5.5%), A.R:R -1.2:1. Score 4.4/10, moderate confidence.
Take-profit target: $92.86 (+2.3% upside). Target $92.86 (+2.4%), stop $85.95 (−5.5%), A.R:R -1.2:1. Stop-loss: $85.95.
Concentration risk — Customer: Abbott Laboratories, Boston Scientific and Medtronic (49.0%); Analyst target reached - limited upside remaining; Weak overall score: 4.4/10.
Integer Holdings Corporation trades at a P/E of 22.6 (forward 13.4). TrendMatrix value score: 5.9/10. Verdict: Hold.
17 analysts cover ITGR with a consensus score of 3.8/5. Average price target: $98.
What does Integer Holdings Corporation do?Integer Holdings is a medical device CDMO manufacturing components and finished devices for Cardio & Vascular, Cardiac...
Integer Holdings is a medical device CDMO manufacturing components and finished devices for Cardio & Vascular, Cardiac Rhythm Management, and Neuromodulation OEM customers from facilities in the U.S., Mexico, Ireland, and other countries. Top 3 customers (Abbott Laboratories, Boston Scientific, Medtronic) collectively represented 49% of 2025 revenues.